The U.S. Food and Drug Administration is seeking public comment on behalf of the United Nations World Health Organization about whether or not CBD should be designated under the 1971 Convention on Psychotropic Substances – the U.S. is a party to that convention.
Other drugs under review include five synthetic opioids similar to fentanyl, and opioid-analgesic Tramadol, fluoroamphetamine, five synthetic cannabinoids akin to those used in the production of Spice and K2, Etizolam, a benzodiazepine like Xanex, the anticonvulsant drug Pregabalin, and Ketamine.
“The [FDA] is requesting interested persons to submit comments concerning abuse potential, actual abuse, medical usefulness, trafficking, and impact of scheduling changes on availability for medical use of 17 drug substances,” the summary states. “These comments will be considered in preparing a response from the [U.S] to the [WHO] regarding the abuse liability and diversion of these drugs. WHO will use this information to consider whether to recommend that certain international restrictions be placed on these drugs.”
In the Federal Register document, the FDA and Department of Health and Human Services admits that CBD “has been shown to be beneficial in experimental models of several neurological disorders, including those of seizure and epilepsy”; however the cannabinoid is still classified under the CSA as a Schedule I drug – meaning regulators, specifically the DEA, contend CBD has “no medicinal value.”
Public comments are being accepted until Sept. 15.